Multicenter Phase-II-Study with Capecitabine/Trastuzumab as first-line therapy for advanced HER2-overexpressing pancreas carcinoma.

Trial Profile

Multicenter Phase-II-Study with Capecitabine/Trastuzumab as first-line therapy for advanced HER2-overexpressing pancreas carcinoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Jul 2012

At a glance

  • Drugs Capecitabine; Trastuzumab
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Jul 2012 Actual end date (May 2008) added as reported by German Clinical Trials Register record.
    • 25 Aug 2011 New source identified and integrated (German Clinical Trials Register record DRKS00000600).
    • 08 Dec 2008 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top